What the discontinuation evidence shows
Published studies summarised in Cochrane reviews and RANZCP adherence resources consistently report that a substantial share of patients discontinue antidepressant treatment in the first 90 days. Reported figures vary by country, study definition, and follow-up window. Whatever the precise figure, the direction is consistent across countries and study designs: most discontinuation happens early, and most of it happens without the prescriber knowing.
Why the first 90 days is structurally difficult
Three factors recur consistently in the clinical literature:
Side effects arrive first. Physical symptoms — nausea, sleep disruption, jitteriness — appear in the first one to two weeks, before any benefit can be assessed. The cost is visible before the return on it is.
The mood effect takes time. Clinical response typically takes four to six weeks to become measurable, and sometimes longer — described consistently in RANZCP and NICE guidance. The gap between discomfort and benefit is where most discontinuation occurs.
Follow-up appointments are weeks apart. The patient manages the experience largely between visits, with limited clinical contact during the period when structural support is most needed. Most guidelines recommend a follow-up within one to two weeks of initiation for this reason.
What the literature suggests is typical at each stage
Side effects most prominent, then begin to ease. Mood typically unchanged. — RANZCP, NICE
Physical side effects mostly resolved. First subtle mood changes commonly appear for those who will respond. — NICE NG222, Maudsley Prescribing Guidelines
Continued steady improvement for many patients; sometimes dose adjustments to optimise response. — RANZCP
A clearer sense of whether the specific medication and dose are the right fit. Major guidelines describe the three-month mark as the typical point for confirming the treatment plan with the prescriber.
What helps, according to the research
Patient self-tracking. Clinical resources including the Royal College of Psychiatrists and NICE describe tracking mood, sleep, and side effects as supporting better follow-up conversations — giving both patient and prescriber something concrete to work with.
Consistent dose timing. TGA and FDA product information consistently recommend regular daily dosing for stable blood levels and reduced side-effect variability.
Early follow-up. Multiple guideline bodies — NICE, RANZCP — recommend the first follow-up within one to two weeks of initiation, precisely the window when structural support is most needed and discontinuation risk is highest.
Informed expectation-setting. Cochrane adherence reviews suggest that patients who are informed in advance about the timeline of side effects and benefits are meaningfully more likely to remain on treatment through the difficult early weeks.
Social support. Telling at least one person in your life about the treatment is associated with better adherence in observational data — accountability and the availability of someone to talk to both appear to matter.
When to bring the appointment forward
- New or worsening suicidal thoughts — contact your prescriber or emergency services immediately
- A sustained spike in anxiety or agitation that is not settling after the first week
- Side effects that are stopping you from sleeping, eating, or functioning — not just uncomfortable, but significantly disruptive
- Any unusual neurological symptoms — confusion, tremor, fever, or a racing heart that is not normal for you
You do not need to wait for the scheduled follow-up. These are exactly the situations every major guideline body says prescribers want to hear about promptly.
Frequently asked questions
Is it actually true that most people stop their antidepressant in the first 90 days?+
Adherence studies and Cochrane reviews consistently show that a substantial share of patients discontinue in this window — reported figures vary but commonly land in the range of 25–50 percent within the first month and 40–70 percent by three months. The direction is well-established across countries; the precise figure varies by study design and population.
What is the most important week to get through?+
Adherence research consistently identifies week two as the highest-risk individual week. Side effects are often still present, the mood benefit has not arrived, and the early commitment to starting treatment has faded. Major guidelines recommend the first follow-up in or near this window for exactly this reason.
What does my prescriber expect me to do during this window?+
Most guidelines describe the patient's role as taking the dose consistently, attending follow-up appointments, raising concerns at those appointments rather than stopping silently, and tracking how the treatment is going so the next conversation has something concrete to work with.
Evidence and sources referenced
- Cochrane Library — reviews of antidepressant adherence interventions and discontinuation outcomes
- RANZCP — Clinical Practice Guidelines for Mood Disorders
- NICE Guideline NG222 — Depression in adults: treatment and management
- NPS MedicineWise — adherence resources for prescribers and patients (Australia)
- Maudsley Prescribing Guidelines in Psychiatry — discontinuation patterns and response timelines
- Royal College of Psychiatrists — patient information on antidepressants
Related articles
Want a clearer record of how you actually felt?
Causiq is being built to help you track the first 90 days simply — so you walk into your next appointment with something concrete to show.
Join the waitlist →